newsfilter
← Latest News
GlobeNewswire·

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient